Smart Nuclide was created in Suzhou Industrial Park,
received seed investment
Smart Nuclide announces the Completion of pre-Series A funding
The first rhTSh product (SNA001) in China receives IND approval from NMPA, Smart Nuclide launches phase I/II clinical trial in Zhongshan Hospital
Smart Nuclide launches Phase III clinical trial of SNA001, completes preliminary preparations for Investigational New Drug Application of SNA002
Smart Nuclide raises nearly CNY 100.0 M in Series B round, granted the “National Science and Technology Major Project for Novel Drug Development Unit”. Smart Nuclide announces the establishment of Radiopharmaceutical Collaborative Innovation Center with Soochow University
Smart Nuclide raises nearly CNY 100.0 M in Series C round, SNA001 completes phase III clinical trial. Smart Nuclide announces the plan to start Investigational New Drug Application (IND) file of SNA002 in the U.S. and China, SNA006 starts investigator-initiated trials (IIT)
SNA001 files the Biologics License Application (BLA) to Center For Drug Evaluation (CDE), SNA002 has started investigator-initiated trials (IIT), received U.S. FDA Clearance and CDE of Clinical Trial, starting the Global clinical trial.
SmartNuclide